156 related articles for article (PubMed ID: 34378790)
1. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders.
Alvarez-Perez B; Poras H; Maldonado R
Br J Pharmacol; 2023 Apr; 180(7):879-893. PubMed ID: 34378790
[TBL] [Abstract][Full Text] [Related]
2. Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.
González-Rodríguez S; Poras H; Menéndez L; Lastra A; Ouimet T; Fournié-Zaluski MC; Roques BP; Baamonde A
Scand J Pain; 2017 Jan; 14():25-38. PubMed ID: 28850427
[TBL] [Abstract][Full Text] [Related]
3. Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.
Southerland WA; Gillis J; Kuppalli S; Fonseca A; Mendelson A; Horine SV; Bansal N; Gulati A
Curr Pain Headache Rep; 2021 Mar; 25(5):29. PubMed ID: 33761014
[TBL] [Abstract][Full Text] [Related]
4. Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs).
Raffa RB; Pergolizzi JV; Taylor R; Ossipov MH;
J Clin Pharm Ther; 2018 Aug; 43(4):443-449. PubMed ID: 29722031
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors.
Mei HR; Hu YY; Kapadia S; Ouimet T; Poras H; Dussor G
Headache; 2023 May; 63(5):621-633. PubMed ID: 37183526
[TBL] [Abstract][Full Text] [Related]
6. Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.
Roques BP
Handb Exp Pharmacol; 2018; 247():53-70. PubMed ID: 27417433
[TBL] [Abstract][Full Text] [Related]
7. Strategies towards safer opioid analgesics-A review of old and upcoming targets.
Varga BR; Streicher JM; Majumdar S
Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881
[TBL] [Abstract][Full Text] [Related]
8. Opioid research in the time of the opioid crisis.
Traynor JR; Moron JA
Br J Pharmacol; 2023 Apr; 180(7):793-796. PubMed ID: 36813266
[TBL] [Abstract][Full Text] [Related]
9. Insights into the mechanisms underlying opioid use disorder and potential treatment strategies.
Cao DN; Li F; Wu N; Li J
Br J Pharmacol; 2023 Apr; 180(7):862-878. PubMed ID: 34128238
[TBL] [Abstract][Full Text] [Related]
10. Emerging areas of opioid pharmacology.
Kelly E; Henderson G; Bailey CP
Br J Pharmacol; 2018 Jul; 175(14):2715-2716. PubMed ID: 29939423
[TBL] [Abstract][Full Text] [Related]
11. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Poras H; Bonnard E; Dangé E; Fournié-Zaluski MC; Roques BP
J Med Chem; 2014 Jul; 57(13):5748-63. PubMed ID: 24927250
[TBL] [Abstract][Full Text] [Related]
12. An in vitro study on the hippocampal epileptogenic properties of enkephalins and enkephalinase inhibitors in rats.
Scotti De Carolis A; Sagratella S; Frank C; Trampus M; Proietti ML
Gen Pharmacol; 1991; 22(4):651-7. PubMed ID: 1657689
[TBL] [Abstract][Full Text] [Related]
13. A novel G protein-biased agonist at the μ opioid receptor induces substantial receptor desensitisation through G protein-coupled receptor kinase.
Groom S; Blum NK; Conibear AE; Disney A; Hill R; Husbands SM; Li Y; Toll L; Kliewer A; Schulz S; Henderson G; Kelly E; Bailey CP
Br J Pharmacol; 2023 Apr; 180(7):943-957. PubMed ID: 33245558
[TBL] [Abstract][Full Text] [Related]
14. Desensitization of mu-opioid receptors does not modify the analgesia induced by an enkephalinase inhibitor.
Bousselmame R; Michael-Titus A; Costentin J
Eur J Pharmacol; 1991 Oct; 203(2):295-7. PubMed ID: 1666049
[TBL] [Abstract][Full Text] [Related]
15. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors.
Maldonado R; Feger J; Fournié-Zaluski MC; Roques BP
Brain Res; 1990 Jun; 520(1-2):247-54. PubMed ID: 2169953
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities.
Gaborit M; Massotte D
Br J Pharmacol; 2023 Apr; 180(7):994-1013. PubMed ID: 34883528
[TBL] [Abstract][Full Text] [Related]
17. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
18. Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.
Roques BP; Noble F
Neurochem Res; 1996 Nov; 21(11):1397-410. PubMed ID: 8947930
[TBL] [Abstract][Full Text] [Related]
19. [The pharmacology of various classes of cerebral opioid receptors].
Roques BP
Ann Endocrinol (Paris); 1986; 47(2):88-96. PubMed ID: 3026230
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains].
Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R
Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
